Rotigaptide (ZP123) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs

@article{Hennan2006RotigaptideP,
  title={Rotigaptide (ZP123) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs},
  author={J. Hennan and R. Swillo and G. A. Morgan and J. Keith and R. Schaub and Robert P. Smith and H. Feldman and K. Haugan and J. Kantrowitz and Phil J. Wang and Aqel Abu-Qare and J. Butera and B. Larsen and D. L. Crandall},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2006},
  volume={317},
  pages={236 - 243}
}
The antiarrhythmic and cardioprotective effect of increasing gap junction intercellular communication during ischemia/reperfusion injury has not been studied. The antiarrhythmic peptide rotigaptide (previously ZP123), which maintains gap junction intercellular communication, was tested in dogs subjected to a 60-min coronary artery occlusion and 4 h of reperfusion. Rotigaptide was administered i.v. 10 min before reperfusion as a bolus + i.v. infusion at doses of 1 ng/kg bolus + 10 ng/kg/h… Expand
Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury.
TLDR
Rotigaptide reduces myocardial infarction size in a porcine model and protects from IRI-related endothelial dysfunction in man and may have therapeutic potential in the treatment of myocardials infarct. Expand
The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs
TLDR
The antiarrhythmic dipeptide ZP1609 (danegaptide) is investigated, which is an analog of the connexin 43 targeting antiarrHythmic peptide rotigaptide (ZP123), in an established and clinically relevant experimental model of ischemia/reperfusion in pigs, and reduces infarct size to a similar extent as ischemic postconditioning. Expand
Effects of Rotigaptide and RIC on Ischemia Reperfusion Injury in the In Vitro Rabbit Heart
TLDR
In contrast to in vivo rIPC, in vitro Rotigaptide did not yield cardioprotection in the authors' rabbit model, but Rotig aptide attenuated the effect of r IPC, which reduced infarct size. Expand
GAP-134 ([2S,4R]-1-[2-Aminoacetyl]4-Benzamidopyrrolidine-2-Carboxylic Acid) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs
TLDR
GAP-134 is an effective antiarrhythmic agent with potential to reduce ischemia/reperfusion injury in dogs subjected to 60-minute and 4-hour reperfusion model. Expand
Effects of rotigaptide (ZP123) on connexin43 remodeling in canine ventricular fibrillation
TLDR
ZP123 reduced Cx43 remodeling through regulating the expression, distribution and phosphorylation of Cx 43, thereby reducing the defibrillation energy required for successful cardioversion. Expand
Testing Danegaptide Effects on Kidney Function after Ischemia/Reperfusion Injury in a New Porcine Two Week Model
TLDR
As expected this porcine renal I/R-I model was associated with reduced GFR two weeks after injury and Danegaptide did not improve renal function after I/ R-I. Expand
Model-Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs
TLDR
The results suggest that gap junction dysfunction may be more important in ischemic AF than in ATP remodeling or congestive heart failure substrates, andRotigaptide improves conduction in various AF models but suppresses AF only for the acute ischemia substrate. Expand
Electrophysiological effect of rotigaptide in rabbits with heart failure
TLDR
Rotigaptide decreases the ERP, elevates VFT, and reduces the vulnerability to ventricular arrhythmias without changing Cx43 expression in rabbits with HF, suggesting it may be a promising antiarrhythmic drug for preventing vent cardiac arrhythmia in HF. Expand
Gap junction modifier rotigaptide decreases the susceptibility to ventricular arrhythmia by enhancing conduction velocity and suppressing discordant alternans during therapeutic hypothermia in isolated rabbit hearts.
TLDR
Testing the hypothesis that rotigaptide can increase ventricular CV, delay the onset of SDA, and decrease the susceptibility to pacing-induced ventricular fibrillation (PIVF) during therapeutic hypothermia found it to protect the hearts against ventricular arrhythmias. Expand
Enhancement of ventricular gap-junction coupling by rotigaptide.
TLDR
It is demonstrated that therapeutic concentrations of rotigaptide increase the resting gap-junction conductance and reduce the magnitude and kinetics of steady-state inactivation in a concentration-dependent manner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Effect of Ramiprilat or Captopril on Myocardial Infarct Size: Assessment in Canine Models of Ischemia Alone and Ischemia with Reperfusion
TLDR
Neither captopril nor ramiprilat protected the heart from injury under conditions of ischemia with reperfusion or ischemies without reperfusions. Expand
Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury.
TLDR
The glycosaminoglycans, heparin or N-acetylheparin, can reduce the extent of myocardial injury associated with regional ischaemia and reperfusion in the canine heart. Expand
Regional contractile blockade at the onset of reperfusion reduces infarct size in the dog heart
TLDR
The results demonstrate that development of necrosis in reperfused myocardium can be greatly reduced by temporary presence of the contractile inhibitor BDM at the onset of reperfusion. Expand
Pretreatment with the gap junction uncoupler heptanol does not limit infarct size in rabbit heart.
TLDR
The results suggest that cell-to-cell communication via gap junctions during coronary artery occlusion does not contribute importantly to the development of necrosis in rabbit heart. Expand
Gap junction uncoupling protects the heart against ischemia.
TLDR
Protection from gap junction uncoupling is not a direct result of a decrease in developed pressure before a prolonged ischemic period nor is it achieved through a mechanism involving the adenosine triphosphate-dependent potassium channel. Expand
Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs.
TLDR
The data with the doses and concentrations used suggest that GJIC may not play a major role in the genesis of focal activity in the ischemic models studied. Expand
Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice.
TLDR
Cx43-deficient mice develop smaller infarcts than wild-type mice following coronary ligation, and new therapies designed to decrease the risk of arrhythmias by enhancing intercellular communication could lead to larger infarCTs caused by persistent coronary occlusion. Expand
Pharmacological Modulation of Cardiac Gap Junctions to Enhance Cardiac Conduction: Evidence Supporting a Novel Target for Antiarrhythmic Therapy
TLDR
It is suggested that ZP123 significantly attenuates gap junction closure during acidosis, suggesting that drug activity targets gap junctions under metabolic stress. Expand
Effects of staged versus sudden reperfusion after acute coronary occlusion in the dog.
TLDR
Function of the ischemic zone failed to improve substantially until day 3 after sudden reperfusion, whereas it improved consistently starting as early as 30 minutes after institution of the staged reperfusions. Expand
The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts.
TLDR
The results suggest that gap junction-mediated transfer of an as-yet unknown 'survival' factor-rather than disrupted transfer of a 'death messenger'-may play a role in the increased resistance to infarction conferred by antecedent PC ischemia in mouse heart. Expand
...
1
2
3
4
5
...